Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas
Clinical trial NCT01660451 · COMPLETED
Trial details
- NCT number
- NCT01660451
- Sponsor
- Bayer
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-11-19
- Primary completion
- 2016-06-22
- Enrollment
- 227
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.